Cited by 288Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Open access

Deng, Rong, Iyer, Suhasini, Theil, Frank-Peter, Mortensen, Deborah L., Fielder, Paul J., Prabhu, Saileta·2011·mAbs

DOI 10.4161/mabs.3.1.13799PMC PMC3038012

Open this paper in CoChat — free account Open PDF

Abstract

The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target mediated mechanisms. These antibody-specific factors need to be considered during prediction of human PK based upon preclinical information. Principles of allometric scaling established for small molecules using data from multiple animal species cannot be directly applied to antibodies. Here, different methods for projecting human clearance (CL) from animal PK data for 13 therapeutic monoclonal antibodies (mAbs) exhibiting linear PK over the tested dose ranges were examined: simple allometric scaling (CL versus body weight), allometric scaling with correction factors, allometric scaling based on rule of exponent and scaling from only cynomolgus monkey PK data. A better correlation was obtained between the observed human CL and the estimated human CL based on cynomolgus monkey PK data and an allometric scaling exponent of 0.85 for CL than other scaling approaches. Human concentration-time profiles were also reasonably predicted from the cynomolgus monkey data using species-invariant time method with a fixed exponent of 0.85 for CL and 1.0 for volume of distribution. In conclusion, we expanded our previous work and others and further confirmed that PK from cynomolgus monkey alone can be successfully scaled to project human PK profiles within linear range using simplify allometry and Dedrick plots with fixed exponent.

Integrity signals

Registry

Crossref · 10.4161/mabs.3.1.13799

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization
West, G. B., & Brown, J. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01589 · Cited by 806
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Animal Scale-Up
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. G. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 270
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257

Show all 24 references

Research works printed but not linked: 1

Deng R, 2007, Prediction of human pharmacokinetics for monoclonal antibody

Sorted by citations

Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Jones, B. E., Brown‐Augsburger, P., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1906 · Cited by 546
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 520
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 342
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Self-citation
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Self-citation
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
Ishiguro, T., Sano, Y., Komatsu, S.-I., Kamata‐Sakurai, M., Kaneko, A., Kinoshita, Y., Shiraiwa, H., Azuma, Y., Tsunenari, T., Kayukawa, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4291 · Cited by 208
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans
Grimm, H. P., Schumacher, V. L., Schäfer, M. K.-H., Imhof-Jung, S., Freskgård, P., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2261509 · Cited by 180
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development
Lai, Y., Chu, X., Di, L., Gao, W., Guo, Y., Liu, X., Lu, C., Mao, J., Shen, H., Tang, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.009 · Cited by 182
A Guide to Rational Dosing of Monoclonal Antibodies
Bai, S., Jorga, K. M., Xin, Y., Jin, D., Zheng, Y., Damico‐Beyer, L. A., Gupta, M., Tang, M. T., Allison, D. E., Lu, D., et al. (2012) · Clinical Pharmacokinetics · doi:10.2165/11596370-000000000-00000 · Cited by 166
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Dokter, W. H. A., Ubink, R., van der Lee, M. M. C., van der Vleuten, M. A. J., van Achterberg, T. A. E., Jacobs, D. C. H., Loosveld, E. M., van den Dobbelsteen, D., Egging, D. F., Mattaar, E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0040-t · Cited by 165
Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies
Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 164
Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
Muto, A. K. T. M., Yoshihashi, K., Takeda, M., Kitazawa, T., Soeda, T., Igawa, T., Sakamoto, Y., Haraya, K., Kawabe, Y., Shima, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12474 · Cited by 150
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Self-citation
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
Yu, X., Robbie, G. J., Wu, Y., Esser, M. T., Jensen, K. M., Schwartz, H. I., Bellamy, T., Hernandez‐Illas, M., & Jafri, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-16 · Cited by 140
Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation
Chapman, K. L., Holzgrefe, H. H., Black, L. E., Brown, M. J., Chellman, G. J., Copeman, C., Couch, J. A., Creton, S. K., Gehen, S. C., Hoberman, A. M., et al. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.03.001 · Cited by 136
Pharmacokinetic Considerations for Antibody Drug Conjugates
Lin, K., & Tibbitts, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0800-y · Cited by 136
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Self-citation
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
Li, B., Tesar, D. B., Boswell, C. A., Cahaya, H. S., Wong, A., Zhang, J., Meng, Y. G., Eigenbrot, C. W., Pantua, H., Diao, J., et al. (2014) · mAbs · doi:10.4161/mabs.29809 · Cited by 122
Self-citation
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
Dobson, C., Devine, P. W. A., Phillips, J. J., Higazi, D. R., Lloyd, C., Popovic, B., Arnold, J., Buchanan, A. G., Lewis, A. R., Goodman, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38644 · Cited by 117
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Waldhauer, I., Gonzalez‐Nicolini, V., Freimoser–Grundschober, A., Nayak, T. K., Fahrni, L., Hosse, R. J., Gerrits, D., Geven, E. J., Sam, J., Lang, S., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1913791 · Cited by 118
Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®
Hoefman, S., Ottevaere, I., Baumeister, J., & Sargentini‐Maier, M. L. (2015) · Antibodies · doi:10.3390/antib4030141 · Cited by 119
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach
Betts, A. M., Keunecke, A., van Steeg, T. J., van der Graaf, P. H., Avery, L. B., Jones, H. M., & Berkhout, J. (2018) · mAbs · doi:10.1080/19420862.2018.1462429 · Cited by 114
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 112
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Avery, L. B., Wang, M., Kavosi, M. S., Joyce, A. P., Kurz, J. C., Fan, Y., Dowty, M. E., Zhang, M., Zhang, Y., Cheng, A., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1193660 · Cited by 109
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein, N. D., Pham, D. T., Schellenberger, U., Buelow, B. D., Boudreau, A. A., Choudhry, P., Clarke, S., Dang, K. H., Harris, K. E., Iyer, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1574521 · Cited by 109
Self-citation
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 101
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
Avery, L. B., Wade, J. M., Wang, M., Tam, A. S. P., King, A. C., Piche‐Nicholas, N., Kavosi, M. S., Penn, S., Cirelli, D. J., Kurz, J. C., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1417718 · Cited by 99
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
Muto, A., Yoshihashi, K., Takeda, M., Kitazawa, T., Soeda, T., Igawa, T., Sampei, Z., Kuramochi, T., Sakamoto, A., Haraya, K., et al. (2014) · Blood · doi:10.1182/blood-2014-07-585737 · Cited by 96
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91
Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins
Kagan, L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059121 · Cited by 92
In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies
Bown, H. K., Bonn, C., Yohe, S. T., Yadav, D. B., Patapoff, T. W., Daugherty, A. L., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.015 · Cited by 92
A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
Bender, B. C., Leipold, D. D., Xu, K., Shen, B., Tibbitts, J., & Friberg, L. E. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9618-3 · Cited by 85
Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
Zhou, C., Lehar, S. M., Gutierrez, J., Rosenberger, C. M., Ljumanovic, N., Dinoso, J. B., Koppada, N., Hong, K., Baruch, A., Carrasco‐Triguero, M., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1229722 · Cited by 83
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics
Bumbaca Yadav, D., Sharma, V. K., Boswell, C. A., Hotzel, I., Tesar, D., Shang, Y., Ying, Y., Fischer, S. K., Grogan, J. L., Chiang, E. Y., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692434 · Cited by 82
Self-citation
Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data
Oitate, M., Masubuchi, N., Ito, T., Yabe, Y., Karibe, T., Aoki, T., Murayama, N., Kurihara, A., Okudaira, N., & Izumi, T. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-011 · Cited by 81
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
Haddish‐Berhane, N., Shah, D. K., Ma, D., Leal, M., Gerber, H., Sapra, P., Barton, H. A., & Betts, A. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9329-x · Cited by 79
Capacity limits of asialoglycoprotein receptor-mediated liver targeting
Bon, C., Höfer, T., Bousquet‐mélou, A., Davies, M. R., & Krippendorff, B. (2017) · mAbs · doi:10.1080/19420862.2017.1373924 · Cited by 78
Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model
Zhao, J., Cao, Y., & Jusko, W. J. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1703-5 · Cited by 78
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering
Ko, S., Jo, M., & Jung, S. T. (2021) · BioDrugs · doi:10.1007/s40259-021-00471-0 · Cited by 74
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Self-citation
An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
Ko, S., Park, S., Sohn, M. H., Jo, M., Ko, B. J., Na, J., Yoo, H., Jeong, A. L., Ha, K., Woo, J. R., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00870-5 · Cited by 71
Anin vitroFcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans
Chung, S., Nguyen, V., Lin, Y. L., Lafrance‐Vanasse, J., Scales, S. J., Lin, K., Deng, R., Williams, K., Sperinde, G. V., Li, J. J., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1605270 · Cited by 65
Self-citation
Clinical Pharmacology of Antibody-Drug Conjugates
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10020020 · Cited by 63
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
Li, C., Zhang, C., Li, Z., Samineni, D., Lu, D., Wang, B., Chen, S., Zhang, R., Agarwal, P., Fine, B. M., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1699768 · Cited by 61
Toward Sensitive and Accurate Analysis of Antibody Biotherapeutics by Liquid Chromatography Coupled with Mass Spectrometry
An, B., Zhang, M., & Qu, J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058917 · Cited by 61
Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A
Gupta, P., Kamath, A. V., Park, S., Chiu, H. H., Lutman, J., Maia, M., Tan, M., Xu, M., Swem, L. R., & Deng, R. (2016) · mAbs · doi:10.1080/19420862.2016.1167294 · Cited by 57
Self-citation
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
Xiang, H., Chan, A., Ahene, A., Bellovin, D., Deng, R., Hsu, A. W., Jeffry, U., Palencia, S., Powers, J. M., Zanghi, J., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1981202 · Cited by 56
Self-citation
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches
Eigenmann, M. J., Karlsen, T. V., Krippendorff, B., Tenstad, O., Fronton, L., Otteneder, M. B., & Wiig, H. (2017) · The Journal of Physiology · doi:10.1113/jp274819 · Cited by 56
Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases
Stefanich, E. G., Rae, J., Sukumaran, S., Lutman, J., Lekkerkerker, A., Ouyang, W., Wang, X., Lee, D., Danilenko, D. M., Diehl, L. J., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.031 · Cited by 55
Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications
Ferl, G. Z., Theil, F., & Wong, H. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1994 · Cited by 54
Self-citation
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
Germovsek, E., Cheng, M., & Giragossian, C. (2021) · mAbs · doi:10.1080/19420862.2021.1964935 · Cited by 56
Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition
Singh, A. P., Krzyżański, W., Martin, S. W., Weber, G. L., Betts, A. M., Ahmad, A. M., Abraham, A. K., Zutshi, A., Lin, J., & Singh, P. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9690-8 · Cited by 53
A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
Davda, J. P., Dodds, M., Gibbs, M. A., Wisdom, W., & Gibbs, J. P. (2014) · mAbs · doi:10.4161/mabs.29095 · Cited by 53
Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions
Qureshi, O. S., Rowley, T. F., Junker, F., Peters, S. J., Crilly, S., Compson, J. E., Eddleston, A., Björkelund, H., Greenslade, K. J., Parkinson, M. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17255-8 · Cited by 53
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 56
Self-citation
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies
Grinshpun, B., Thorsteinson, N., Pereira, J. N., Rippmann, F., Nannemann, D., Sood, V. D., & Fomekong Nanfack, Y. (2021) · mAbs · doi:10.1080/19420862.2021.1932230 · Cited by 52
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
Chen, X., Haddish‐Berhane, N., Moore, P. A., Clark, T., Yang, Y., Li, H., Xuan, D., Barton, H. A., Am, B., & Barletta, F. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.393 · Cited by 52
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1)
Singh, A. P., & Shah, D. K. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0071-y · Cited by 50
A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Jones, H. M., Zhang, Z., Jasper, P., Luo, H., Avery, L. B., King, L. E., Neubert, H., Barton, H. A., Betts, A. M., & Webster, R. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12461 · Cited by 48
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
Yoshida, K. J., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H. H., Honigberg, L. A., Jin, J. Y., & Quartino, A. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48
Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys
Gu, J.-M., Zhao, X.-Y., Schwarz, T., Schuhmacher, J., Baumann, A., Ho, E., Subramanyan, B., Tran, K., Myles, T., Patel, C., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0086-4 · Cited by 45
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
Harris, K. E., Lorentsen, K. J., Malik-Chaudhry, H. K., Loughlin, K., Basappa, H. M., Hartstein, S., Ahmil, G., Allen, N. S., Avanzino, B. C., Balasubramani, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90096-8 · Cited by 44
Self-citation
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
Davé, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E., Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1210747 · Cited by 43
Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate againstStaphylococcus aureus
Deng, R., Zhou, C., Li, D., Cai, H., Sukumaran, S., Carrasco‐Triguero, M., Saad, O. M., Nazzal, D., Lowe, C., Ramanujan, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1627152 · Cited by 42
Self-citation
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1806-6 · Cited by 41
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas
de Lucas, Á. G., Schuhmacher, A. J., Oteo, M., Romero, E., Cámara, J. A., Martino, A. D., Arroyo, A. G., Morcillo, M. Á., Squatrito, M., Martinez-Torrecuadrada, J. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158634 · Cited by 41
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
Brennan, F. R., Polli, J. R., Sathish, J. G., Ramones, M., Wolf, B., Schlothauer, T., Peters, S. J., Maier, C. C., Ji, C., Wensel, D. L., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2505092 · Cited by 44
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB
Dudal, S., Hinton, H. J., Giusti, A. M., Bacac, M., Muller, M., Fauti, T., Colombetti, S., Heckel, T., Giroud, N., Klein, C., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000132 · Cited by 39
Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans
Xin, Y., Bai, S., Damico‐Beyer, L. A., Jin, D., Liang, W., Wu, Y., Theil, F., Joshi, A., Lu, Y., Lowe, J. A., III, et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0781-x · Cited by 38
Self-citation
Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats
Yip, V., Lee, M. V., Saad, O. M., Ma, S., Khojasteh, S. C., & Shen, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061323 · Cited by 37
Prediction of Human Plasma Concentration-time Profiles of Monoclonal Antibodies from Monkey Data by a Species-invariant Time Method
Oitate, M., Nakayama, S., Ito, T., Kurihara, A., Okudaira, N., & Izumi, T. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-sh-059 · Cited by 35
A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
Ferl, G. Z., Reyes, A. E., Sun, L. L., Cheu, M., Oldendorp, A., Ramanujan, S., & Stefanich, E. G. (2018) · Clinical and Translational Science · doi:10.1111/cts.12535 · Cited by 35
Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
Saeheng, T., Na‐Bangchang, K., & Karbwang, J. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2513-6 · Cited by 35
Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin
Li, D., Lee, D., Dere, R. C., Zheng, B., Yu, S., Fuh, F. K., Kozak, K. R., Chung, S., Yadav, D. B., Nazzal, D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14784 · Cited by 35
Self-citation
Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Xiang, H., Bender, B. C., Reyes, A. E., Merchant, M. A., Jumbe, N. L. ‘., Romero, M., Davancaze, T., Nijem, I., Mai, E., Young, J. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0260 · Cited by 35
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates
Ong, E. Z., Budigi, Y., Tan, H. C., Robinson, L. N., Rowley, K. J., Winnett, A. V., Hobbie, S. N., Shriver, Z. H., Babcock, G. J., & Ooi, E. E. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.05.007 · Cited by 34
First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer
Richter, A., Knorr, K., Schlapschy, M., Robu, S., Morath, V., Mendler, C. T., Yen, H.-Y., Steiger, K., Kiechle, M. B., Weber, W., et al. (2020) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-020-00638-7 · Cited by 34
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
Schultink, A. H. M. D. V., Doornbos, R. P., Bakker, A. B. H., Bol, K., Throsby, M., Geuijen, C. A. W., Maussang, D., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0593-x · Cited by 34
Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
Haraya, K., Tsutsui, H., Komori, Y., & Tachibana, T. (2022) · Pharmaceuticals · doi:10.3390/ph15050508 · Cited by 35
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies
Mortensen, D. L., Prabhu, S., Stefanich, E. G., Fischer, S. K., Gelzleichter, T. R., Baker, D., Jiang, J. Z., Wallace, K., Iyer, S., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.22216 · Cited by 33
Self-citation
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 33
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
Frances, N., Bacac, M., Bray, K. M., Christen, F., Hinton, H. J., Husar, E., Quackenbush, E. J., Schäfer, M. K.-H., Schick, E., Vyver, A. J. V. D., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.12.019 · Cited by 33
Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies
Kratochwil, N. A., Dueker, S. R., Muri, D., Senn, C., Yoon, H., Yu, B. Y., Lee, G., Dong, F., & Otteneder, M. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205435 · Cited by 32
Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
Li, C., Zhang, C., Deng, R., Leipold, D. D., Li, D., Latifi, B., Gao, Y., Zhang, C., Li, Z., Miles, D., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12649 · Cited by 34
Self-citation
Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation
Shen, H., Yang, Z., & Rodrigues, A. D. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000695 · Cited by 32
Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats
Kagan, L., Zhao, J., & Mager, D. E. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1416-1 · Cited by 32
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 31
Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans
Wang, H., Rangan, V. S., Sung, M., Passmore, D., Kempe, T., Wang, X., Thevanayagam, L., Pan, C., Rao, C. M., Srinivasan, M., et al. (2015) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1953 · Cited by 31
A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy
Le, K. N., Gibiansky, L. V., Good, J., Davancaze, T., Campagne, M. V. L., Loyet, K. M., Morimoto, A. M., Jin, J., Damico‐Beyer, L. A., & Hanley, W. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227223 · Cited by 31
Isoform-selective TGF-β3 inhibition for systemic sclerosis
Sun, T., Heiden, J. A. V., Gao, X., Yin, J., Uttarwar, S., Liang, W., Jia, G., Yadav, R., Huang, Z., Mitra, M. S., et al. (2024) · Med · doi:10.1016/j.medj.2023.12.011 · Cited by 32
Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT‐981 Against IL‐1α and IL‐1β in Healthy Subjects and Patients With Osteoarthritis of the Knee
Kosloski, M. P., Goss, S. L., Wang, S. X., Liu, J., Loebbert, R. W., Medema, J. K., Liu, W. Y., & Dutta, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.764 · Cited by 30
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
Haraya, K., Tachibana, T., Nanami, M., & Ishigai, M. (2014) · Xenobiotica · doi:10.3109/00498254.2014.941963 · Cited by 30
Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies
Peters, S. A., Petersson, C., Blaukat, A., Halle, J.-P., & Dolgos, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.002 · Cited by 28

Authors: Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S.
Affiliations: Genentech (US)
Corresponding author: Deng, Rong
ORCID: Deng, Rong
Iyer, Suhasini
Theil, Frank-Peter
Prabhu, Saileta
Venue: mAbs
Publisher: Informa UK Limited
Published: 2011-01
Volume: 3
Issue: 1
Pages: 61-66
ISSN: 1942-0862 (ISSN-L)
1942-0870
DOI: 10.4161/mabs.3.1.13799
PMC: PMC3038012
OpenAlex: W1555185942
Cited by: 285
References: 24
Citations by year: 2026: 16 · 2025: 13 · 2024: 25 · 2023: 10 · 2022: 17 · 2021: 27 · 2020: 15 · 2019: 19 · 2018: 18 · 2017: 19 · 2016: 23 · 2015: 24 · 2014: 14 · 2013: 21 · 2012: 14
FWCI: 14.18
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
Locations: mAbs (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Genentech
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: therapeutic monoclonal antibodies, human pharmacokinetics, allometric scaling, clearance prediction, Macaca fascicularis, volume of distribution
MeSH terms: Algorithms, Animals, Antibodies, Monoclonal, Drug Evaluation, Preclinical, Humans, Macaca fascicularis, Metabolic Clearance Rate, Models, Biological, Species Specificity, Mice, Rats, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks